Holen Sie sich die Stockscreener-App
14.14
0.78%
0.11
Vorhandelsmarkt:
13.85
-0.29
-2.05%
Schlusskurs vom Vortag:
$14.03
Offen:
$14.27
24-Stunden-Volumen:
665.48K
Relative Volume:
0.96
Marktkapitalisierung:
$1.29B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-4.5761
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+2.32%
1M Leistung:
-8.77%
6M Leistung:
-0.98%
1J Leistung:
-7.82%
1-Tages-Spanne:
$13.99
$14.36
1-Wochen-Bereich:
$13.81
$14.52
52-Wochen-Spanne:
$13.51
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
14.14 | 1.29B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Financial Survey: Barinthus Biotherapeutics (NASDAQ:BRNS) & Arcus Biosciences (NYSE:RCUS) - Defense World
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer - BioSpace
Arcus Biosciences appoints new Chief Medical Officer - Investing.com
Arcus Biosciences appoints new Chief Medical Officer By Investing.com - Investing.com UK
Arcus Biosciences Announces New Chief Medical Officer - TipRanks
Arcus Biosciences Names Amgen Veteran Richard Markus as CMO to Lead Expanding Phase 3 Pipeline - StockTitan
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Buy" by Analysts - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Buy” by Analysts - Defense World
Wells Fargo Initiates Coverage of Arcus Biosciences (RCUS) with Overweight Recommendation - MSN
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
How the (RCUS) price action is used to our Advantage - Stock Traders Daily
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025 - Seeking Alpha
Arcus Biosciences stock hits 52-week low at $13.51 By Investing.com - Investing.com Canada
Arcus Biosciences (NYSE:RCUS) Sets New 52-Week LowTime to Sell? - MarketBeat
Arcus: Excellent Pipeline And Collaborations, Cash Runway (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS investor three-year losses grow to 60% as the stock sheds US$79m this past week - Simply Wall St
Robert C. Goeltz II Sells 3,594 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) Stock - MarketBeat
Principal Financial Group Inc. Sells 18,777 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Geode Capital Management LLC Has $18.69 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays PLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Barclays PLC - MarketBeat
(RCUS) Trading Report - Stock Traders Daily
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Buy” by Brokerages - Defense World
Arcus Biosciences Grants Stock Options, RSUs to New Employees Under Inducement Plan - StockTitan
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week - Yahoo Finance
Jane Street Group LLC Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
State Street Corp Lowers Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences to Present at J.P. Morgan Healthcare Conference 2025Key Oncology Updates Expected - StockTitan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 26,966 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
BNP Paribas Financial Markets Has $173,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
(RCUS) Trading Advice - Stock Traders Daily
Arcus Biosciences' SWOT analysis: stock outlook amid HIF2alpha and TIGIT progress - Investing.com
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS) - Simply Wall St
Charles Schwab Investment Management Inc. Has $8.67 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Announces New Employment Inducement Grants - Marketscreener.com
Arcus Biosciences Awards New Employee Equity Grants Under Inducement Plan - StockTitan
Fmr LLC Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Point72 Asset Management L.P. Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
(RCUS) Investment Analysis and Advice - Stock Traders Daily
Arcus Biosciences' chief accounting officer sells $3,079 in stock - Investing.com
Arcus Biosciences' chief accounting officer sells $3,079 in stock By Investing.com - Investing.com Canada
Parkman Healthcare Partners LLC Acquires 610,219 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Grants New Employee Stock Options and RSUs in Latest Inducement Awards - StockTitan
Walleye Capital LLC Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Suvretta Capital Management LLC Trims Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Algert Global LLC Has $1.73 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus up 4% following Merck Welireg kidney cancer data - MSN
When (RCUS) Moves Investors should Listen - Stock Traders Daily
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $14.24 Million Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):